Søren Cortnum
YOU?
Author Swipe
View article: Impact of norepinephrine versus phenylephrine on brain circulation, organ blood flow and tissue oxygenation in anaesthetised patients with brain tumours: study protocol for a randomised controlled trial
Impact of norepinephrine versus phenylephrine on brain circulation, organ blood flow and tissue oxygenation in anaesthetised patients with brain tumours: study protocol for a randomised controlled trial Open
Introduction Vasopressor support is often preferred as an efficient and convenient way to raise the blood pressure during surgery and intensive care therapy. However, the optimal vasopressor for ensuring organ blood flow and tissue oxygen …
View article: Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial
Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial Open
Abstract BackgroundStudies suggest that high intensities of tumor treating fields (TTFields) correlate with prolonged survival in newly diagnosed glioblastoma. However, no randomized clinical studies have tested different doses of TTFields…
View article: CNSC-22. GLIOBLASTOMA CELLS EXHIBIT NEURON-LIKE EXCITABILITY IN BOTH ACUTE AND ORGANOTYPIC HUMAN BRAIN SLICES
CNSC-22. GLIOBLASTOMA CELLS EXHIBIT NEURON-LIKE EXCITABILITY IN BOTH ACUTE AND ORGANOTYPIC HUMAN BRAIN SLICES Open
Glioblastomas (GBM) are known for their significant intratumor heterogeneity, featuring a variety of plastic cell types that make effective treatment challenging. Recent studies have shown that neuronal-progenitor-like transcriptomic cell …
View article: Glioblastoma cells imitate neuronal excitability in humans
Glioblastoma cells imitate neuronal excitability in humans Open
Background: Glioblastomas are renowned for their pronounced intratumoral heterogeneity, characterized by a diverse array of plastic cell types. However, the physiological and transcriptomic features of the cells residing in the invasive le…
View article: von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance
von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance Open
von Hippel Lindau disease (vHL) is caused by a hereditary predisposition to multiple neoplasms, especially hemangioblastomas in the retina and CNS, renal cell carcinomas (RCC), pheochromocytomas, neuroendocrine pancreatic tumours (PNET) an…
View article: ETMR-01. TREATMENT OUTCOME OF TWO CASES WITH HIGH-GRADE NEUROEPITHELIAL TUMOR WITH BCOR ALTERATION
ETMR-01. TREATMENT OUTCOME OF TWO CASES WITH HIGH-GRADE NEUROEPITHELIAL TUMOR WITH BCOR ALTERATION Open
INTRODUCTION High grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication (HGNET BCOR) is a recently described tumor entity of the central nervous system (CNS) with a distinct methylation profile and characteristic geneti…
View article: OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma
OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma Open
Background Preclinical studies suggest that skull remodeling surgery (SR-surgery) increases the dose of tumor treating fields (TTFields) in glioblastoma (GBM) and prevents wasteful current shunting through the skin. SR-surgery introduces m…
View article: SURG-01. OPTIMALTTF-1: FINAL RESULTS OF A PHASE 1 STUDY: FIRST GLIOBLASTOMA RECURRENCE EXAMINING TARGETED SKULL REMODELING SURGERY TO ENHANCE TUMOR TREATING FIELDS STRENGTH
SURG-01. OPTIMALTTF-1: FINAL RESULTS OF A PHASE 1 STUDY: FIRST GLIOBLASTOMA RECURRENCE EXAMINING TARGETED SKULL REMODELING SURGERY TO ENHANCE TUMOR TREATING FIELDS STRENGTH Open
BACKGROUND OptimalTTF-1(open-label phase-1) combines Tumor Treating Fields(TTFields) treatment with targeted skull-remodeling surgery(SR-surgery) aiming to enhance the electric field strength in the tumor(NCT02893137). SR-surgery aims to r…
View article: P05.03 OptimalTTF-1: Final results of a phase 1 study at first glioblastoma recurrence examining targeted craniotomy to enhance Tumor Treating Fields intensity
P05.03 OptimalTTF-1: Final results of a phase 1 study at first glioblastoma recurrence examining targeted craniotomy to enhance Tumor Treating Fields intensity Open
BACKGROUND OptimalTTF-1 is an open-label phase-1 study on the combination of Tumor Treating Fields (TTFields) treatment together with targeted skull remodeling surgery aiming to enhance the electric field intensity in the brain (NCT0289313…
View article: ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)
ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1) Open
We present a pre-specified interim analysis of an ongoing open-label, phase-1 IST (NCT02893137) testing safety/efficacy of a new rGBM treatment. The intervention combines personalized skull-remodeling (SR) surgery with TTFields and best-ch…
View article: P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1)
P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1) Open
We present a pre-specified interim analysis of an ongoing open-label, investigator-sponsored phase 1 trial (NCT02893137) testing safety/efficacy of a new rGBM treatment. The intervention combines personalized skull-remodeling (SR) surgery …
View article: ACTR-54. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED INTERVENTION WITH SKULL REMODELLING SURGERY TO MAXIMIZE LEVELS OF TTFIELDS INTENSITY FOR HIGHER TREATMENT BENEFIT - THE OPTIMAL TTF STUDY
ACTR-54. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED INTERVENTION WITH SKULL REMODELLING SURGERY TO MAXIMIZE LEVELS OF TTFIELDS INTENSITY FOR HIGHER TREATMENT BENEFIT - THE OPTIMAL TTF STUDY Open
We present an ongoing open label phase 1 investigator-sponsored trial (NCT02893137) testing safety/efficacy of a novel therapeutic concept for recurrent glioblastoma (GBM). The intervention combines best choice chemotherapy with tumor trea…